Related references
Note: Only part of the references are listed.Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial
Hsien-Yuan Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia Secondary Analysis of a Randomized Clinical Trial
Chieh-Hsin Lin et al.
JAMA NETWORK OPEN (2021)
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton et al.
SCHIZOPHRENIA RESEARCH (2020)
Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis A Randomized Clinical Trial
James G. Scott et al.
JAMA NETWORK OPEN (2020)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders A Randomized Clinical Trial
Daniel C. Javitt et al.
JAMA PSYCHIATRY (2018)
Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh-Hsin Lin et al.
BIOLOGICAL PSYCHIATRY (2018)
Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Chun-Yuan Lin et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)
Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway
Saki Shimizu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia
Bruce J. Kinon et al.
BIOLOGICAL PSYCHIATRY (2015)
Clinical and Electrophysiological Effects of D-Serine in a Schizophrenia Patient Positive for Anti-N-Methyl- D-Aspartate Receptor Antibodies
Uriel Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Targeting of NMDA receptors in new treatments for schizophrenia
Kenji Hashimoto
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht et al.
JAMA PSYCHIATRY (2014)
A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
Athan Spiros et al.
FRONTIERS IN PHARMACOLOGY (2014)
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Kenji Hashimoto et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2013)
Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia
Francesco Errico et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Pierre Paoletti et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Daniel C. Javitt et al.
SCHIZOPHRENIA BULLETIN (2012)
Plasma levels of D-serine in Brazilian individuals with schizophrenia
Marilia A. Calcia et al.
SCHIZOPHRENIA RESEARCH (2012)
Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis
Ricardo E. Carrion et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia
Michael F. Green et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Serine racemase and the serine shuttle between neurons and astrocytes
Herman Wolosker
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression
Maxwell Bennett
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2009)
Cortical Development and Glutamatergic Dysregulation in Schizophrenia
Akira Sawa
BIOLOGICAL PSYCHIATRY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
John McGrath et al.
EPIDEMIOLOGIC REVIEWS (2008)
Synthesis and biological evaluation of D-amino acid oxidase inhibitors
Dana Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Physiological functions of D-amino acid oxidases: from yeast to humans
L. Pollegioni et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia
Inna Bendikov et al.
SCHIZOPHRENIA RESEARCH (2007)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2006)
Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms
Siegfried Kasper
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
The neurochemica circuitry of schizophrenia
A Carlsson
PHARMACOPSYCHIATRY (2006)
Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
K Hashimoto et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2005)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia
GC Tsai et al.
BIOLOGICAL PSYCHIATRY (2004)
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2004)
Decreased serum levels of D-serine in patients with schizophrenia - Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
K Hashimoto et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor
JP Mothet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
